It's a Wrap: 18 New Pharma-Bio Facilities Complete Construction in 1Q08, an Industrial Info News AlertHighlighted Links

It's a Wrap: 18 New Pharma-Bio Facilities Complete Construction in 1Q08, an Industrial Info News AlertHighlighted Links 

Industrial Info ResourcesSUGAR LAND, TX - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- The first three months of 2008 saw 18 new pharmaceutical-biotech sites wrap up construction throughout North America. The projects included research and development laboratories and full-scale manufacturing plants. The current capital-spending trends within the industry were definitely reflected within the first-quarter results, with projects sourced out of the medical device sector, the federal government, universities and contract manufacturers. All of the new construction activity was drawn from a recent analysis of new plant development monitored in Industrial Info's Pharmaceutical Tracker.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=131834, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR) is a marketing information service specializing in industrial process, energy and financial related markets with products and services ranging from industry news, analytics, forecasting, plant and project databases, as well as multimedia services. For more information send inquiries to [email protected] or visit us at www.industrialinfo.com.

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.